Fukami, Hirotaka http://orcid.org/0000-0002-7375-0748
Morinaga, Jun http://orcid.org/0000-0002-6196-6023
Nakagami, Hironori http://orcid.org/0000-0003-4494-3601
Hayashi, Hiroki
Okadome, Yusuke
Matsunaga, Eiji
Kadomatsu, Tsuyoshi http://orcid.org/0000-0003-3327-6954
Horiguchi, Haruki
Sato, Michio
Sugizaki, Taichi
Miyata, Keishi
Torigoe, Daisuke
Mukoyama, Masashi
Morishita, Ryuichi
Oike, Yuichi http://orcid.org/0000-0003-3245-5395
Funding for this research was provided by:
Ono Medical Research Foundation
MEXT | Japan Society for the Promotion of Science (21K20935, 22K16429)
Japan Agency for Medical Research and Development (JP23ym0126809)
KM Biologics Co., Ltd. and FunPep Co., Ltd.
Article History
Received: 23 May 2023
Accepted: 13 October 2023
First Online: 1 November 2023
Competing interests
: A patent on the vaccine targeting ANGPTL3 as treatment for dyslipidemia and associated disease has been filed (PCT/JP2022/020850; Y.Oike, J.M., H.F.). Y.Oike is financially supported by KM Biologics and Funpep. R.M. and H.N. are stockholders of FunPep. H.N. is a scientific advisor for FunPep. The Department of Health Development and Medicine is an endowed department supported by AnGes, Daicel, and FunPep, and collaborates with these companies. The Department of Clinical Gene Therapy is financially supported by Novartis, AnGes, Shionogi, Boehringer, Fancl, Rohto, and FunPep. The remaining authors declare no competing interests.